Lenacapavir Sodium Patent Expiration
Lenacapavir Sodium is Used for treating HIV-1 infection with multidrug resistance in heavily treatment-experienced adults when combined with other antiretrovirals. It was first introduced by Gilead Sciences Inc
Lenacapavir Sodium Patents
Given below is the list of patents protecting Lenacapavir Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sunlenca | US11944611 | Capsid inhibitors for the treatment of HIV | Jun 04, 2041 | Gilead Sciences Inc |
| Sunlenca | US11944611 | Capsid inhibitors for the treatment of HIV | Jun 04, 2041 | Gilead Sciences Inc |
| Sunlenca | US11267799 | Solid forms of an HIV capsid inhibitor | Aug 16, 2038 | Gilead Sciences Inc |
| Sunlenca | US10071985 | Therapeutic compounds | Aug 17, 2037 | Gilead Sciences Inc |
| Sunlenca | US10654827 | Therapeutic compounds | Aug 17, 2037 | Gilead Sciences Inc |
| Sunlenca | US9951043 | Therapeutic compounds | Feb 28, 2034 | Gilead Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lenacapavir Sodium's patents.
Latest Legal Activities on Lenacapavir Sodium's Patents
Given below is the list recent legal activities going on the following patents of Lenacapavir Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 07 Jun, 2024 | US11944611 |
| Petition Entered | 30 May, 2024 | US11944611 |
| Second letter to regulating agency to determine regulatory review period | 10 May, 2024 | US9951043 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944611 |
| Recordation of Patent Grant Mailed Critical | 02 Apr, 2024 | US11944611 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Apr, 2024 | US11944611 |
| Patent eGrant Notification | 02 Apr, 2024 | US11944611 |
| Email Notification Critical | 02 Apr, 2024 | US11944611 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944611 |
| Email Notification Critical | 14 Mar, 2024 | US11944611 |
Lenacapavir Sodium's Family Patents
